Zobrazeno 1 - 10
of 190
pro vyhledávání: '"Hemming, Johansson"'
Autor:
Maria Andersson, Hemming Johansson, Anders Österborg, Agneta Månsson-Broberg, Lotta Hansson, Marzia Palma
Publikováno v:
HemaSphere, Vol 7, p e28011bd (2023)
Externí odkaz:
https://doaj.org/article/23d76477eef84b0387e4be7393b66b8d
Autor:
Magnus Nilsson, Halla Olafsdottir, Gabriella Alexandersson von Döbeln, Fernanda Villegas, Giovanna Gagliardi, Mats Hellström, Qiao-Li Wang, Hemming Johansson, Val Gebski, Jakob Hedberg, Fredrik Klevebro, Sheraz Markar, Elizabeth Smyth, Pernilla Lagergren, Ghazwan Al-Haidari, Lars Cato Rekstad, Eirik Kjus Aahlin, Bengt Wallner, David Edholm, Jan Johansson, Eva Szabo, John V. Reynolds, CS Pramesh, Naveen Mummudi, Amit Joshi, Lorenzo Ferri, Rebecca KS Wong, Chris O’Callaghan, Jelena Lukovic, Kelvin KW Chan, Trevor Leong, Andrew Barbour, Mark Smithers, Yin Li, Xiaozheng Kang, Feng-Ming Kong, Yin-Kai Chao, Tom Crosby, Christiane Bruns, Hanneke van Laarhoven, Mark van Berge Henegouwen, Richard van Hillegersberg, Riccardo Rosati, Guillaume Piessen, Giovanni de Manzoni, Florian Lordick
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe globally dominant treatment with curative intent for locally advanced esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemoradiotherapy (nCRT) with subsequent esophagectomy. This multimodal treatment leads to around 60% overall
Externí odkaz:
https://doaj.org/article/c303a3a5e5d942c9a1b8efb0a9d35233
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 4, p 3838 (2023)
The main prognostic factors for patients with head and neck cancer are the tumour site and stage, yet immunological and metabolic factors are certainly important, although knowledge is still limited. Expression of the biomarker p16INK4a (p16) in orop
Externí odkaz:
https://doaj.org/article/df475faad9814974a0f6d81d7980cae9
Autor:
Lucy Bai, MD, Kerstin Sandelin, MD, PhD, Marie Wickman, MD, PhD, Brita Arver, MD, PhD, Ola Lundström, Medical Photographer, Hemming Johansson, Statistician, Yvonne Brandberg, Psychologist, PhD
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 9, Iss 5, p e3561 (2021)
Background:. The cosmetic results after risk-reducing mastectomy (RRM) and immediate breast reconstruction (IBR) are intended to be long-lasting. Long-term follow-up of the cosmetic outcome can be evaluated subjectively by the women themselves throug
Externí odkaz:
https://doaj.org/article/5a6e89fcf15b41f4a498e8f95e531816
Autor:
Nina Groes Kofoed, Henrik Falconer, Hanna Vanky, Hemming Johansson, Mirna Abraham-Nordling, Sahar Salehi
Publikováno v:
Gynecologic Oncology. 170:259-265
Autor:
Alexios Matikas, Hemming Johansson, Per Grybäck, Judith Bjöhle, Balazs Acs, Ceren Boyaci, Tobias Lekberg, Hanna Fredholm, Ellinor Elinder, Sara Margolin, Erika Isaksson-Friman, Ana Bosch, Henrik Lindman, Jamila Adra, Anne Andersson, Susanne Agartz, Mats Hellström, Ioannis Zerdes, Johan Hartman, Jonas Bergh, Thomas Hatschek, Theodoros Foukakis
Publikováno v:
Clinical Cancer Research. 29:532-540
Purpose: PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Rates of pathologic complete response (pCR) did not differ
Autor:
Johan Falkenius, Hemming Johansson, Rainer Tuominen, Marianne Frostvik Stolt, Johan Hansson, Suzanne Egyhazi Brage
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background The variable prognosis in stage III cutaneous melanoma is partially due to unknown prognostic factors. Improved prognostic tools are required to define patients with an increased risk of developing metastatic disease who might ben
Externí odkaz:
https://doaj.org/article/5fa8545fb29f49a5a271587254cb505a
Autor:
Jana de Boniface, Jan Frisell, Yvette Andersson, Leif Bergkvist, Johan Ahlgren, Lisa Rydén, Roger Olofsson Bagge, Malin Sund, Hemming Johansson, Dan Lundstedt, on behalf of the SENOMAC Trialists’ Group
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-7 (2017)
Abstract Background The role of axillary lymph node dissection (ALND) has increasingly been called into question among patients with positive sentinel lymph nodes. Two recent trials have failed to show a survival difference in sentinel node-positive
Externí odkaz:
https://doaj.org/article/b044cb4b1bdb459780c39a8415765434
Autor:
Sandra Eketorp Sylvan, Anna Asklid, Hemming Johansson, Jenny Klintman, Jenny Bjellvi, Staffan Tolvgård, Eva Kimby, Stefan Norin, Per-Ola Andersson, Claes Karlsson, Karin Karlsson, Birgitta Lauri, Mattias Mattsson, Anna Bergendahl Sandstedt, Maria Strandberg, Anders Österborg, Lotta Hansson
Publikováno v:
Haematologica, Vol 104, Iss 4 (2019)
The aim of this study was to investigate long-term outcome following first-line therapy in consecutive chronic lymphocytic leukemia (CLL) patients in a well-defined geographic area: Sweden. All patients diagnosed with CLL (2007–2013) (n=3672) were
Externí odkaz:
https://doaj.org/article/f8ee6428d9824583bdf7bcb653686120
Autor:
Theodoros Foukakis, Thomas Hatschek, Jonas Bergh, Johan Hartman, Ioannis Zerdes, Mats Hellström, Susanne Agartz, Anne Andersson, Jamila Adra, Henrik Lindman, Ana Bosch, Erika Isaksson-Friman, Sara Margolin, Ellinor Elinder, Hanna Fredholm, Tobias Lekberg, Ceren Boyaci, Balazs Acs, Judith Bjöhle, Per Grybäck, Hemming Johansson, Alexios Matikas
Supplementary Table S1. Representativeness of Study Participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a20ac4c195bec17379ecd7d458547c
https://doi.org/10.1158/1078-0432.22490726.v1
https://doi.org/10.1158/1078-0432.22490726.v1